Bases moleculares de la inmunotoxicología experimental de la marihuana

Publicado

2006-10-01

Bases moleculares de la inmunotoxicología experimental de la marihuana

Molecular bases of experimental immunotoxicology of marijuana

Palabras clave:

cannabis, abuso de marihuana, toxicología, fenómenos bioquímicos, canabinoides, sistema inmunológico. (es)
cannabis, marijuana abuse, toxicology, biochemical phenomena, cannabinoids, immune system (en)

Descargas

PDF
HTML

Autores/as

Guillermo Orlando Narváez Quintero Químico Farmacéutico, MSc en Bioquímica. Universidad Nacional de Colombia, Bogotá
Carlos Arturo Guerrero Fonseca Médico MSc en Farmacología, MSc en Genética, PhD, Profesor Asociado, Facultad de Medicina, Universidad Nacional de Colombia, Bogotá.

Resumen (es)
Resumen (en)

La marihuana es una de las drogas de abuso más antiguas conocidas por la humanidad. Sin embargo, sólo recientemente se han comenzado a comprender los mecanismos bioquímicos que están detrás de los efectos toxicos de la droga en el sistema inmune. Los modelos experimentales in vitro e in vivo , tanto en animales como en humanos, muestran un claro patrón de alteración inmunológica, apuntando hacia la supresión de la respesta inmune de tipo celular Th1-dependiente. En estos eventos la participación de los receptores para canabinoides expresados en la superficie de los inmunocitos es muy importante.

Marijuana is one of the oldest drugs known by humankind; however, only recently the biochemical mechanism behind the toxicodinamics effects have begun becoming clear. The experimental models, in vitro and in vivo, both in animals and humans, show a clear tendency of immune alteration, pointing out suppression of the Th1-dependent immune response. In these events the involvement of cannabinoid receptors on the surface of immunocites are remarkable.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Berdyshev EV. Cannabinoid receptors and the regulation of immune response. Chem Phys Lipids 2000;108:169-90.

Straus SE. Immunoactive cannabinoids: therapeutic prospects for marijuana constituents. Proc Natl Acad Sci USA . 2000; 97: 9363-4.

Devane WA, Dysarz FA, 3rd, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol. 1988; 34: 605-13.

Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-4.

Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61-5.

Nahas GG, Suciu-Foca N, Armand JP, Morishima A. Inhibition of cellular mediated immunity in marihuana smokers. Science . 1974;183:419-20.

Tindall B, Cooper DA, Donovan B, Barnes T, Philpot CR, Gold J, et al. The Sydney AIDS Project: development of acquired immunodeficiency syndrome in a group of HIV seropositive homosexual men. Aust N Z J Med. 1988;18:8-15.

Cabral GA, Dove Pettit DA. Drugs and immunity: cannabinoids and their role in decreased resistance to infectious disease. J Neuroimmunol . 1998;83:116-23.

Friedman H, Newton C, Klein TW. Microbial infections, immunomodulation, and drugs of abuse. Clin Microbiol Rev . 2003;16:209-19.

Lutz B. Molecular biology of cannabinoid receptors. Prostaglandins Leukot Essent Fatty Acids . 2002;66:123-42.

Roth MD, Baldwin GC, Tashkin DP. Effects of delta- 9 -tetrahydrocannabinol on human immune function and host defense. Chem Phys Lipids . 2002;121:229-39.

Bouaboula M, Rinaldi M, Carayon P, Carillon C, Delpech B, Shire D, et al. Cannabinoid-receptor expression in human leukocytes. Eur J Biochem. 1993;214:173-80.

Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995; 232: 54-61.

Marchand J, Bord A, Penarier G, Laure F, Carayon P, Casellas P. Quantitative method to determine mRNA levels by reverse transcriptase-polymerase chain reaction from leukocyte subsets purified by fluorescence-activated cell sorting: application to peripheral cannabinoid receptors. Cytometry. 1999;35:227-34.

Matias I, Pochard P, Orlando P, Salzet M, Pestel J, Di Marzo V. Presence and regulation of the endocannabinoid system in human dendritic cells. Eur J Biochem . 2002;269:3771-8.

Klein TW, Newton C, Larsen K, Lu L, Perkins I, Nong L, et al. The cannabinoid system and immune modulation. J Leukoc Biol. 2003;74:486-96.

Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002;54:161-202.

Kaminski NE. Regulation of the cAMP cascade, gene expression and immune function by cannabinoid receptors. J Neuroimmunol. 1998;83:124-32.

Howlett AC, Qualy JM, Khachatrian LL. Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol Pharmacol. 1986;29:307-13.

Kaminski NE, Koh WS, Yang KH, Lee M, Kessler FK. Suppression of the humoral immune response by cannabinoids is partially mediated through inhibition of adenylate cyclase by a pertussis toxin-sensitive G-protein coupled mechanism. Biochem Pharmacol 1994;48:1899-908.

Herring AC, Faubert Kaplan BL, Kaminski NE. Modulation of CREB and NF-kappaB signal transduction by cannabinol in activated thymocytes. Cell Signal 2001;13:241-50.

Condie R, Herring A, Koh WS, Lee M, Kaminski NE. Cannabinoid inhibition of adenylate cyclase-mediated signal transduction and interleukin 2 (IL-2) expression in the murine T-cell line, EL4.IL-2. J Biol Chem . 1996;271:13175-83.

Herring AC, Kaminski NE. Cannabinol-mediated inhibition of nuclear factor-kappaB, cAMP response element-binding protein, and interleukin-2 secretion by activated thymocytes. J Pharmacol Exp Ther. 1999;291:1156-63.

Borish LC, Steinke JW. 2. Cytokines and chemokines. J Allergy Clin Immunol. 2003;111:S460-75.

Kaminski NE. Inhibition of the cAMP signaling cascade via cannabinoid receptors: a putative mechanism of immune modulation by cannabinoid compounds. Toxicol Lett. 1998;102-103:59-63.

Kaminski NE. Immune regulation by cannabinoid compounds through the inhibition of the cyclic AMP signaling cascade and altered gene expression. Biochem Pharmacol. 1996;52:1133-40.

Faubert BL, Kaminski NE. AP-1 activity is negatively regulated by cannabinol through inhibition of its protein components, c-fos and c-jun. J Leukoc Biol. 2000;67:259-66.

Yea SS, Yang KH, Kaminski NE. Role of nuclear factor of activated T-cells and activator protein- 1 in the inhibition of interleukin-2 gene transcription by cannabinol in EL4 T-cells. J Pharmacol Exp Ther. 2000;292:597-605.

Klein TW, Newton CA, Nakachi N, Friedman H. Delta 9-tetrahydrocannabinol treatment suppresses immunity and early IFN-gamma, IL-12, and IL-12 receptor beta 2 responses to Legionella pneumophila infection. J Immunol. 2000;164:6461-6.

Newton CA , Klein TW, Friedman H. Secondary immunity to Legionella pneumophila and Th1 activity are suppressed by delta-9-tetrahydrocannabinol injection. Infect Immun. 1994;62:4015-20.

Tateda K, Matsumoto T, Ishii Y, Furuya N, Ohno A, Miyazaki S, et al. Serum cytokines in patients with Legionella pneumonia: relative predominance of Th1-type cytokines. Clin Diagn Lab Immunol. 1998;5:401-3.

Zhu LX, Sharma S, Stolina M, Gardner B, Roth MD, Tashkin DP, et al. Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol. 2000;165:373-80.

McKallip RJ, Nagarkatti M, Nagarkatti PS. Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J Immunol. 2005;174:3281-9.

Gardner B, Zu LX, Sharma S, Liu Q, Makriyannis A, Tashkin DP, et al. Autocrine and paracrine regulation of lymphocyte CB2 receptor expression by TGF-beta. Biochem Biophys Res Commun. 2002;290:91-6.

Farrar JD, Asnagli H, Murphy KM. T helper subset development: roles of instruction, selection, and transcription. J Clin Invest. 2002;109:431-5.

Yuan M, Kiertscher SM, Cheng Q, Zoumalan R, Tashkin DP, Roth MD. Delta 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. J Neuroimmunol. 2002;133:124-31.

Kaplan BL, Rockwell CE, Kaminski NE. Evidence for cannabinoid receptor-dependent and -independent mechanisms of action in leukocytes. J Pharmacol Exp Ther. 2003;306:1077-85.

Wu TC, Tashkin DP, Djahed B, Rose JE. Pulmonary hazards of smoking marijuana as compared with tobacco. N Engl J Med. 1988;318:347-51.

Baldwin GC, Tashkin DP, Buckley DM, Park AN, Dubinett SM, Roth MD. Marijuana and cocaine impair alveolar macrophage function and cytokine production. Am J Respir Crit Care Med. 1997;156:1606-13.

Shay AH, Choi R, Whittaker K, Salehi K, Kitchen CM, Tashkin DP, et al. Impairment of antimicrobial activity and nitric oxide production in alveolar macrophages from smokers of marijuana and cocaine. J Infect Dis. 2003;187:700-4.

MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol. 1997;15:323-50.

Bogdan C. Nitric oxide and the immune response. Nat Immunol. 2001;2:907-16.

Galea E, Feinstein DL. Regulation of the expression of the inflammatory nitric oxide synthase (NOS2) by cyclic AMP. Faseb J. 1999;13:2125-37.

Nong L, Newton C, Cheng Q, Friedman H, Roth MD, Klein TW. Altered cannabinoid receptor mRNA expression in peripheral blood mononuclear cells from marijuana smokers. J Neuroimmunol. 2002;127:169-76.

Córdoba D. Toxicologia. El Manual Moderno Ltda; 2001:401.

National Highway Traffic Safety Administration. http://www.nhtsa.dot.gov/People/injury/research/job185drugs/cannabis.htm

Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J Anal Toxicol. 1992;16:276-82.

Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. II. Models for the prediction of time of marijuana exposure from plasma concentrations of delta 9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta 9-tetrahydrocannabinol (THCCOOH). J Anal Toxicol. 1992;16:283-90.

Azorlosa J, Heishman S, Stitzer M, Mahaffey J. Marijuana smoking: effect of varying delta 9-tetrahydrocannabinol content and number of puffs. J Pharmacol Exp Ther. 1992;261:114-122.

Ashton CH. Adverse effects of cannabis and cannabinoids. Br J Anaesth. 1999;83:637-49.

Pacifici R, Zuccaro P, Pichini S, Roset PN, Poudevida S, Farre M, et al. Modulation of the Immune System in Cannabis Users. JAMA. 2003;289:1929-a-1931.

Khalsa J, Genser S, Francis H, Martin B. Clinical consequences of marijuana. J Clin Pharmacol. 2002;42:7S-10.

Sidney S, Beck J, Tekawa I, Quesenberry C, Friedman G. Marijuana use and mortality. Am J Public Health. 1997;87:585-590.